Trump Administration Eases Access to Experimental Peptide Drugs

An-Nahar: The Trump Administration is easing access to experimental peptide drugs despite safety concerns, amid medical debate over the effectiveness of these drugs and their growing market in America, and warnings about their risks…
Machine translation of an attributed source excerpt. Consult the original report to verify details. Translated from original reporting in another language.


